Treatment of patients with obesity, insulin resistance, and T2D is rapidly changing with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonist treatments such as liraglutide and semaglutide [70,71,72]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.